Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment [2]

European Journal of Anaesthesiology

Volumn 21, Issue 7, 2004, Pages 572-574

  Krivosic Horber, Renée ^a   Depret T ^a   Wagner, J M ^b   Maurage, C A ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; STATIN;

ADULT; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; FATIGUE; HUMAN; HYPERCHOLESTEROLEMIA; LETTER; MALE; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCLE CRAMP; MYOPATHY; VASTUS LATERALIS MUSCLE;

ADULT; BIOLOGICAL MARKERS; CREATINE KINASE; FATIGUE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MALIGNANT HYPERTHERMIA; MIDDLE AGED; MUSCLE CRAMP; PEDIGREE;

EID: 3342960763     PISSN: 02650215     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0265021504227120     Document Type: Letter

References (6)

1. Farmer JA. Learning from the cerivastatin experience. Lancet 2001; 358: 383-385.
2. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 2000; 22: 441-457.
3. Urwyler A, Deufel T, McCarthy T, West S. European Malignant Hyperthermia Group. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-287.
4. Weglinski MR, Wedel DJ, Engel AG. Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 1997; 84: 1038-1041.
5. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-572.
6. Ording H. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH group. Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997; 41: 955-966.